Antimycobacterial Activities of N-Substituted-Glycinyl 1H-1,2,3-Triazolyl Oxazolidinones and Analytical Method Development and Validation for a Representative Compound.

Twelve -substituted-glycinyl triazolyl oxazolidinone derivatives were screened for antimycobacterial activity against susceptible ( ( H37Rv) and resistant (isoniazid (INH)-resistant (SRI 1369), rifampin (RMP)-resistant (SRI 1367), and ofloxacin (OFX)-resistant (SRI 4000)) strains. Most of the compounds showed moderate to strong antimycobacterial activity against all strains tested, with minimum inhibitory concentration (MIC) value ranges of 0.5-11.5, 0.056-11.6, 0.11-5.8, and 0.03-11.6 μM, and percent inhibition ranges of 41-79%, 51-72%, 50-75%, and 52-71% against H37Rv, INH-R, RMP-R, and OFX-R , respectively. The 3,5-dinitrobenzoyl and 5-nitrofuroyl derivatives demonstrated strong antimycobacterial activities with the -(5-nitrofuroyl) derivatives ( and ) being the most potent, with MIC value range of 0.3-0.6 μM against all strains tested. Compounds were not bactericidal, but showed intracellular (macrophage) antimycobacterial activity. A reliable validated analytical method was developed for a representative compound using Waters Acquity ultra High-Performance Liquid Chromatography (UHPLC) system with quaternary Solvent Manager (H-Class). A simple extraction method indicated that was stable in human plasma after 90 min at 37 °C with more than 90% successfully recovered. Moreover, stress stability studies were performed and degradants were identified by using UHPLC-ESI-QToF under acidic, basic, and oxidative simulated conditions.